Revance Therapeutics — Technical Presentation (December 2018)
37 slides from Revance Therapeutics's technical presentation, Dec 4, 2018
Slide 1: SAKURA 3 Open-Label Phase 3 Safety Study Topline Results
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Topline Results Presented by Dan Browne, Co-Founder, President & CEO, and Roman G. Rubio, MD, Senior Vice President of Clinical Development 4 December 2018
Slide 2: Forward-Looking Statements / Safe Harbor / Market Data
Forward-Looking Statements / Safe Harbor / Market Data “Revance Therapeutics”, TransMTS, “Remarkable Science. Enduring Performance”, and the Revance logo are registered trademarks of Revance Therapeutics, Inc. All other trademarks or registered trademarks are the property of their respective owners.
Slide 3: Licensing Agreement - Ideal Partnership for RT002 in China
Fosun Group is one of China’s largest private industrial and investment conglomerates Upfront: $30M Total milestones: $200M+ Tiered royalties: low-double-digit up to high-teens There will be no transfer of intellectual property Fosun Pharma has exclusive rights to develop, commercialize & distribute
Slide 4: SAKURA Open-Label Safety Study Top-Line Results with RT002
SAKURA 3 Open-Label Safety Study Top-Line Results with RT002 in Glabellar Lines Completion of the largest-ever aesthetic neuromodulator clinical program paves the way for BLA filing 1H 2019 SAFETY – Well-tolerated across 3,800 treatments in glabellar (frown) lines Adverse events were mild, localized
Slide 5: Open-Label Phase 3 Safety Study Results
Open-Label Phase 3 Safety Study Results Presented by Roman G. Rubio, MD Senior Vice President of Clinical Development
Slide 6: SAKURA Clinical Trial – Largest-Ever Aesthetic Neuromodulator Clinical Program
SAKURA Clinical Trial – Largest-Ever Aesthetic Neuromodulator Clinical Program *U.S. only **U.S. and Canada SAKURA 1 Pivotal: 36 Weeks N = 303 Treatment Centers: 15* DAXI 201 Placebo 102 SAKURA 3 Open-Label, Long-term Safety: 84 Weeks Total: Over 2,800 patients received more than 4,200 DAXI 40U trea
Slide 7: Study Objective and Endpoints
Study Objective and Endpoints 1 Safety evaluable population includes all subjects exposed to the investigational product 2 Conducted for overall trial summary and by treatment period Study Objective: To evaluate the long-term safety of DaxibotulinumtoxinA for Injection (RT002) for the treatment of m
Slide 8: Study Designs
SAKURA 1 and 2 Study Designs Two Pivotal Phase 3 Studies identical in design (total N = 609) evaluating the Efficacy and Safety of DaxibotulinumtoxinA for Injection over 36 Weeks for the Treatment of Moderate-to-Severe Glabellar Lines at 30 sites across U.S. and Canada N=303 2:1 Randomization Week 0
Slide 9: SAKURA 3 Open-Label Safety Study Design
SAKURA 3 Open-Label Safety (OLS) Study Design A prospective, 84 week Open-Label, Repeat Dose Study evaluating the Safety and Effectiveness of DaxibotulinumtoxinA for Injection to Treat Moderate-to-Severe Glabellar Lines conducted at 66 sites across U.S. and Canada DAXI 40U Treatment 3 DAXI 40U Treat
Slide 10: Frown Wrinkle Severity Scales
Frown Wrinkle Severity Scales Both investigators and subjects trained at trial initiation on a validated 4-point Wrinkle Severity Scale to assess severity of glabellar frown lines At entry, subjects were required to have glabellar line wrinkle severity of either Moderate or Severe as assessed by bot
Slide 11: Disposition
Disposition N (%) Number of Subjects Enrolled 2,691 Number of Subjects who Completed Study 2,314 (86.0%) Number of Subjects who Discontinued Study 377 (14.0%) Reasons for Discontinuation Withdrawal by Subject 196 (7.3%) Lost to Follow up 99 (3.7%) Protocol Deviation 53 (2.0%) Other 15 (0.6%) Investi
Slide 12: Total in SAKURA 3 Treatments Received
Total in SAKURA 3 Number of Subjects 2,691 DAXI 40U Treatment Received in OLS Treatment Cycle #1 2,380 Treatment Cycle #2 882 Treatment Cycle #3 568 Total Number of Treatments 3,830 Subject Disposition SAKURA 3 OLS enrolled nearly 2,700 subjects to fulfill FDA requirement of at least 2,100 single tr
Slide 13: Demographics
Demographics SAKURA 1 & 2 DAXI Pooled (N=405) SAKURA 3 OLS (N=2691) Female, n (%) 357 (88.1%) 2383 (88.6%) Age (years), mean (SD) range [min, max] 50.2 (1.46) [21, 74] 49.5 (11.27) [21, 86] Race White 353 (87.2%) 2407 (89.4%) Black/African American 19 (4.7%) 129 (4.8%) Asian 18 (4.4%) 73 (2.7%) Othe
Slide 14: Baseline Characteristics
Baseline Characteristics SAKURA 1 & 2 DAXI Pooled (N=405) SAKURA 3 OLS (N=2691) Prior BoNT-A*, n (%) 213 (52.6) 1074 (39.9%) Months since last BoNT-A* mean (SD) range 27.4 (1.59) [7, 205] 34.9 (41.78) [0.2, 320] PFWS at Maximum Frown Moderate 226 (55.8) 1482 (55.1%) Severe 179 (44.2%) 1208 (44.9%) I
Slide 15: Summary of Adverse Events Regardless of Causality
Summary of Adverse Events Regardless of Causality SAKURA 3 OLS Compared with SAKURA 1 and 2 SAKURA 1 & 2 DAXI Pooled (N=406) n (%) SAKURA 3 OLS (N=2691) n (%) Death* 0 1 (<0.1%) Serious AEs (SAE) 4 (1.0%) 29 (1.1%) Subjects with any AE 166 (40.9) 1043 (38.8%) Mild 124 (30.5%) 739 (27.5%) Moderate 36
Slide 16: Adverse Events Regardless of Causality (≥2% in OLS)
Adverse Events Regardless of Causality (≥2% in OLS) SAKURA 3 OLS Compared with SAKURA 1 and 2 Preferred Term SAKURA 1 & 2 Pooled (N=406) n (%) SAKURA 3 OLS (N=2691) n (%) Headache 37 (9.1%) 158 (5.9%) Nasopharyngitis 17 (4.2%) 119 (4.4%) Injection site pain 15 (3.7%) 105 (3.9%) Injection site erythe
Slide 17: Treatment-Related Adverse Events (≥1% in OLS)
Treatment-Related Adverse Events (≥1% in OLS) SAKURA 3 OLS Compared with SAKURA 1 and 2 AE Incidence Rates DAXI 40U Treatments in SAKURA 3 Preferred Term SAKURA 1 & 2 Pooled (N=406) n (%) SAKURA 3 (N=2691) n (%) Treatment Cycle 1 (N=2380) n (%) Treatment Cycle 2 (N=882) n (%) Treatment Cycle 3 (N=56
Slide 18: None or Mild Response Rate over Time on IGA-FWS and PFWS
None or Mild Response Rate over Time on IGA-FWS and PFWS WEEK SAKURA 1 & 2 Pooled (%) n=405 SAKURA 3 Treatment Cycle ONE (%) n=2380 TWO (%) n=882 THREE (%) n=568 1 93.8 91.8 91.5 92.3 2 95.8 96.6 93.9 96.1 4 97.5 95.8 96.6 97.7 8 93.1 91.6 92.2 93.7 12 86.2 81.2 83.9 84.5 16 72.6 67.6 59.4 -- 20 53.
Slide 19: None or Mild Response Rate by IGA-FWS over Time
None or Mild Response Rate by IGA-FWS over Time SAKURA 3 OLS Compared with SAKURA 1 and 2 SAKURA 1, 2, and 3 Study Outcomes for None or Mild Response on IGA-FWS Consistent Between Studies and Treatment Cycles
Slide 20: None or Mild Response Rate by PFWS over Time
None or Mild Response Rate by PFWS over Time SAKURA 3 OLS Compared with SAKURA 1 and 2 SAKURA 1, 2, and 3 Study Outcomes for None or Mild Response on PFWS Consistent Between Studies and Treatment Cycles
Slide 21: Proportion Achieving ≥2 Point Composite Response at Week 4
Proportion of Subjects Who Achieve ≥2 Point Composite Response at Max Frown at Week 4 in SAKURA 1, 2, and 3 Two-Point Composite Response Comparable Across Studies and Treatment Cycles SAKURA 1 and 2 SAKURA 3 OLS * p<0.001 vs placebo of 0% (SAKURA 1) and 1% (SAKURA 2)
Slide 22: Time to Loss of None or Mild Wrinkle Severity
Time to Loss of None or Mild Wrinkle Severity on Both IGA-FWS and PFWS SAKURA 3 OLS Compared with SAKURA 1 and 2 Data shown include Treatment 1 for OLS Group B (i.e, De Novo + Received Placebo in SAKURA 1 or 2), Treatment 2 for both Groups A and B, and results from SAKURA 1 and 2 studies. Median Dur
Slide 23: Time to Return to Baseline on Both IGA-FWS and PFWS
Time to Return to Baseline on Both IGA-FWS and PFWS SAKURA 3 OLS Compared with SAKURA 1 and 2 Data shown are for the first two Treatments of OLS Group B (i.e, De Novo + Received Placebo in SAKURA 1 or 2), and results from SAKURA 1 and 2 studies. Median Duration of 28 Weeks Achieved in SAKURA 3 Treat
Slide 24: Investigator and Subject Assessment by GAIS
Investigator and Subject Assessment of Improvement by Study Global Aesthetic Improvement Scale (GAIS)* Both Investigator and Subject Assessment of Improvement (Score ≥ +1) on GAIS Remained Consistently High at Week 4 Across SAKURA 1, 2, and 3 OLS Investigator GAIS Subject GAIS % of Subjects *7-Point
Slide 25: Median Time to Loss of None or Mild by Subgroup
Median Time to Loss of None or Mild on Both IGA-FWS and PFWS by Subgroup No Prior Toxin (n=1617) Prior Toxin (n=1074) All (n=2691) Treatment Duration of 24 Weeks Achieved Regardless of Age and Prior Toxin Experience
Slide 26: Median Time to Return to Baseline by Subgroup
Median Time to Return to Baseline on Both IGA-FWS and PFWS by Subgroup No Prior Toxin (n=1617) Prior Toxin (n=1074) All (n=2691) Treatment Duration of 28 Weeks Achieved in <65 yrs Subgroup and Regardless of Prior Toxin Experience, with Duration Extended to 31.4 Weeks in 65 yrs or Older Subgroup
Slide 27: Example 2-Point Improvement in 23 Year Old Female
BASELINE Week 16 Week 24 Example 2-Point Improvement by IGA-FWS & PFWS at Week 4 Two Point Sustained Duration of Effect through Week 16 and 1-point Improvement Sustained Through Week 24 in 23 year old Female Week 4 IGA-FWS: 0 PFWS: 0 IGA-FWS: 0 PFWS: 0 IGA-FWS: 1 PFWS: 1 IGA-FWS: 2 PFWS: 2
Slide 28: One Point Improvement Sustained through Week 24 in 44 yo Female
BASELINE Week 16 Week 24 Example 2-Point Improvement by IGA-FWS & PFWS at Week 4 Week 4 IGA-FWS: 0 PFWS: 0 IGA-FWS: 1 PFWS: 1 IGA-FWS: 1 PFWS: 2 IGA-FWS: 2 PFWS: 2 One Point Improvement Sustained through Week 24 by Investigator Assessment in 44 yo Female
Slide 29: One Point Sustained Duration of Effect in 53 yo Male
BASELINE Week 16 Week 24 Example 2-Point Improvement by IGA-FWS & PFWS at Week 4 Week 4 IGA-FWS: 0 PFWS: 0 IGA-FWS: 0 PFWS: 1 IGA-FWS: 1 PFWS: 2 IGA-FWS: 2 PFWS: 2 One Point Sustained Duration of Effect through Week 24 by Investigator Assessment in 53 yo Male
Slide 30: Safety Summary – DaxibotulinumtoxinA for Injection
Safety Summary – 1 DaxibotulinumtoxinA for Injection SAKURA 3 OLS confirmed the safety profile of DaxibotulinumtoxinA for Injection (DAXI) 40U established in the SAKURA 1 and 2 pivotal studies, with no new tolerability or safety concerns reported, and stable or decreasing rates of AEs following repe
Slide 31: Safety Summary – Treatment-Related Adverse Events and Eyelid Ptosis
Safety Summary – 2 DaxibotulinumtoxinA for Injection Treatment-related Adverse Events were experienced in fewer treatments (≈14%) in SAKURA 3 OLS across 66 clinical trial sites, compared with the pivotal SAKURA 1 and 2 studies (≈18%) conducted at 30 sites The most frequently occurring treatment-rela
Slide 32: Efficacy Summary
Efficacy Summary DaxibotulinumtoxinA for Injection SAKURA 3 OLS demonstrated efficacy that exceeded or was comparable to that seen in the SAKURA 1 and 2 pivotal studies with DAXI at a dose of 40U. Efficacy of DAXI was highly consistent across successive treatment cycles and multiple endpoints evalua
Slide 33: Duration of Effect Summary
Duration of Effect Summary DaxibotulinumtoxinA for Injection SAKURA OLS results confirm the long duration of clinical benefit observed with the 40U dose of DAXI in SAKURA 1 and 2 and demonstrate consistency across treatment cycles. Median time to return to baseline GL severity was 28 weeks in treatm
Slide 34: U.S. Neuromodulator Molecular Landscape
U.S. Neuromodulator Molecular Landscape RT002 and onabotulinumtoxinA have a nearly identical amount of core active ingredient
Slide 35: Commercial-Ready Manufacturing Platform Located in the U.S.
Commercial-Ready Manufacturing Platform Located in the U.S. US Based Manufacturing for both Drug Substance and Drug Product State-of-the-Art Commercial-ready cGMP facility CMC/Analytics: US Select Agent License Drug Substance Capability to manufacture botulinum neurotoxin type A from 150 kD to 900 k
Slide 36: Expanding Studies of RT002 – Seven in Total
RT002 NEUROSCIENCE Cervical Dystonia Plantar Fasciitis Upper Limb Spasticity Chronic Migraine Preclinical Phase 1 Phase 2 Phase 3 RT002 AESTHETICS Glabellar (Frown) Lines Forehead Lines Lateral Canthal Lines (Crow’s Feet) Expanding Studies of RT002 – Seven in Total New for 2019 New for 2019 File 1H
Slide 37: Revance – Remarkable Science. Enduring Performance.
s* revance REMARKABLE SCIENCE. ENDURING PERFORMANCE:
Revance Therapeutics — Technical Presentation (December 2018) on 6ix